Peptide profile
Tesamorelin: the brand, the indication and the clinic quote.
Why EGRIFTA WR and a provider’s tesamorelin program need separate price comparisons.
The ingredient file
The name is just the beginning.
Identify the preparation, its evidence and its approval context before comparing the price.
Peptide evidence profiles
Peptide profile
VIP nasal pricing: what the subscription does—and does not—tell you.
Keep vasoactive intestinal peptide’s commercial terms separate from approval and clinical claims.
Peptide profile
Oxytocin: a familiar name does not identify the product.
Why an obstetric injection label cannot validate an unspecified wellness preparation.
Peptide profile
BPC-157 and TB-500: read the evidence before the price.
Provider menus, research compounds and regulatory discussions are different kinds of evidence.
Peptide profile
CJC-1295 and ipamorelin: a blend needs two evidence checks.
A combination name and a vial price leave important identity and safety questions unanswered.
Peptide profile
Retatrutide and cagrilintide: a trial is not a retail offer.
Why an investigational compound should not be presented as an ordinary compounded GLP-1 option.
Peptide profile
MOTS-c: cellular research does not settle a treatment price.
A mitochondrial peptide profile with the human-evidence gaps kept visible.
Looking for an advertised treatment?
Price boards retain the product route, supply, care fees and source. Some research compounds have evidence profiles without a purchase comparison.
Browse all price boards →